Login to Your Account



So far so good with Abivax's first-in-class Rev inhibitor ABX464

By Cormac Sheridan
Staff Writer

Thursday, February 25, 2016

DUBLIN – Abivax SA has seen enough of an efficacy signal in a phase IIa trial of its first-in-class HIV drug ABX464 to warrant another phase IIa, to test its potential to delay viral rebound after cessation of therapy.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription